Please assess the completion status of the following clinical trial:

Trial Title: Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Participants must meet all of the following criteria:~* Male or Female patients 18 years and older.~* Patient with a diagnosis of chronic myelogenous leukemia in chronic phase~* Within 6 months of initial diagnosis.~* Received any treatment for CML for less than 1 month prior to study entry with the exception of hydroxyurea and/or anagrelide.~Exclusion Criteria:~* Late chronic phase, accelerated phase or blastic phase~* Taking any other investigational agents within 28 days of starting the study~* If sibling donors have been identified and where allogeneic bone marrow transplantation will be the first line treatment.~* Another primary malignancy /cancer unless it is not considered clinically significant or does not require active intervention.~* If patients have heart problems or complications~* Pregnant or breast-feeding females~* Severe and/or uncontrolled disease such as diabetes, chronic renal disease, etc.~* Chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).~* Diagnosis of human immunodeficiency virus (HIV) infection.~* Received any treatment for CML for longer than 1 month prior to study entry with the exception of hydroxyurea and/or anagrelide.~* Patient previously received radiotherapy to greater than 25% of the bone marrow.~* Patient had a major surgery within 4 weeks prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).